EDITAS MEDICINE INC(NASDAQ:EDIT) stock News

EDIT Latest News, Press Relases and Analysis

All

Press Releases

15 days ago - By: Benzinga - Mentions: ILMN VRTX LLY NVO ...

My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years

a month ago - By: Benzinga

Editas Medicine Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

3 months ago - By: The Motley Fool - Mentions: SRPT

2 Beaten-Down Stocks to Avoid

4 months ago - By: The Motley Fool

Editas Medicine Is Great. Here's Why You Shouldn't Buy It.

a month ago - By: Zacks Investment Research - Mentions: CRMD KNSA PHAR

Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol

a month ago - By: Editas Medicine, Inc.

Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate

a month ago - By: Editas Medicine, Inc.

Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate

a month ago - By: Editas Medicine, Inc.

Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate

a month ago - By: Editas Medicine, Inc.

Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate

a month ago - By: Editas Medicine, Inc.

Editas Medicine to Participate in Upcoming Investor Conferences

a month ago - By: Editas Medicine, Inc.

Editas Medicine to Participate in Upcoming Investor Conferences

2 months ago - By: Zacks Investment Research - Mentions: DARE

Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates

2 months ago - By: Editas Medicine, Inc.

Editas Medicine Announces Second Quarter 2025 Results and Business Updates

2 months ago - By: Editas Medicine, Inc.

Editas Medicine Announces Second Quarter 2025 Results and Business Updates

2 months ago - By: Zacks Investment Research - Mentions: TCRX

TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Beats Revenue Estimates

2 months ago - By: Zacks Investment Research - Mentions: HUMA

Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates

4 months ago - By: Yahoo Finance - Mentions: WWD NTLA BAC

Editas Medicine Is Great. Here's Why You Shouldn't Buy It.

4 months ago - By: Investor's Business Daily - Mentions: LLY VERV NTLA CRSP ...

Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover

4 months ago - By: Editas Medicine, Inc.

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June

4 months ago - By: Editas Medicine, Inc.

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June

4 months ago - By: Yahoo Finance - Mentions: BAC O EPD LMT ...

1 Stock Down 97% That Could Double, According to Wall Street

4 months ago - By: Yahoo Finance - Mentions: TSM O AAPL AMZN ...

4 Reasons to Buy Taiwan Semiconductor Manufacturing Stock Like There's No Tomorrow

5 months ago - By: Editas Medicine, Inc.

Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June

5 months ago - By: Editas Medicine, Inc.

Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June

5 months ago - By: Zacks Investment Research - Mentions: EXEL ALLO

EDITAS MEDICINE INC (EDIT) Stock News

EDIT Latest News, Press Relases and Analysis

My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years

Editas Medicine Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

2 Beaten-Down Stocks to Avoid

Editas Medicine Is Great. Here's Why You Shouldn't Buy It.

Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol

Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate

Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate

Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate

Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate

Editas Medicine to Participate in Upcoming Investor Conferences

Editas Medicine to Participate in Upcoming Investor Conferences

Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates

Editas Medicine Announces Second Quarter 2025 Results and Business Updates

Editas Medicine Announces Second Quarter 2025 Results and Business Updates

TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Beats Revenue Estimates

Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates

Editas Medicine Is Great. Here's Why You Shouldn't Buy It.

Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June

1 Stock Down 97% That Could Double, According to Wall Street

4 Reasons to Buy Taiwan Semiconductor Manufacturing Stock Like There's No Tomorrow

Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June

Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June

EXEL Q1 Earnings Beat, 2025 Sales View Up as Cabometyx Drives Top Line